Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Metabolomic Profile of Weight Gain of People Living with HIV Treated with Integrase Strand Transfer Inhibitor Regimens Reveals Dysregulated Lipid Metabolism and Mitochondrial Dysfunction.
Ascencio-Anastacio AM, Larios-Serrato V, Mata-Marín JA, Rodríguez Evaristo M, Núñez-Armendáriz M, Cano-Díaz AL, Chaparro-Sánchez A, Salinas-Velázquez GE, Maldonado-Rodríguez A, Torres J, García-Flores MM, Martínez-Valencia ZE, Arroyo-Sánchez BI, Olin-Sandoval V, Minauro F, Gaytán-Martínez JE, Pompa-Mera EN. Ascencio-Anastacio AM, et al. Metabolites. 2025 Oct 25;15(11):695. doi: 10.3390/metabo15110695. Metabolites. 2025. PMID: 41295281 Free PMC article.
Methods: We conducted a nested case-control study within the randomized clinical trial MICTLAN (NCT06629480). Sixty-six participants were randomized to receive INSTI-based regimens, either bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) or dolutegravir/abacav …
Methods: We conducted a nested case-control study within the randomized clinical trial MICTLAN (NCT06629480). Sixty-six participants …
Effectiveness and safety of dolutegravir/lamivudine/abacavir versus bictegravir/emtricitabine/tenofovir alafenamide as first-line regimens in real-world settings (MICTLAN study).
Mata-Marín JA, Rodríguez-Evaristo MS, Cano-Díaz AL, Valenzuela-Salazar MDR, Chaparro-Sánchez A, Triana-González S, Hernández-López O, Pompa-Mera EN, Padilla-Noguera PE, Gaytán-Martínez JE; MICTLAN study group. Mata-Marín JA, et al. Int J STD AIDS. 2026 Mar;37(4):363-370. doi: 10.1177/09564624251396720. Epub 2025 Nov 18. Int J STD AIDS. 2026. PMID: 41250998 Clinical Trial.
Incidence of metabolic syndrome in people with HIV who start dolutegravir based-regimen compared with bictegravir based-regimen after 48 weeks.
Mata Marín JA, Rodríguez Evaristo MS, Cano Díaz AL, Salinas Velázquez GE, Triana González S, Chaparro Sánchez A, Pompa Mera E, Meneses Cisneros B, Gaytán Martínez JE; MICTLAN study group. Mata Marín JA, et al. AIDS. 2025 Oct 1;39(12):1731-1738. doi: 10.1097/QAD.0000000000004259. Epub 2025 Jun 4. AIDS. 2025. PMID: 40478899 Clinical Trial.